Polyethylene Glycol Topical Application for Herpes Relapse Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for herpes labialis, such as acyclovir, are expensive, have reduced efficacy due to viral resistance, and suffer from patient compliance issues, necessitating an alternative approach to manage relapse and prevention.
Innovation Solution
Topical application of polyethylene glycol (PEG) on the lips and surrounding facial skin to reduce, delay, or prevent relapse of herpes labialis, with administration periods ranging from at least 4 weeks to indefinitely, utilizing its hygroscopic properties to create an environment less conducive to virus replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If acyclovir is used to treat herpes labialis, then antiviral efficacy is achieved, but cost increases and viral resistance develops
Solution Approach 1:
The patent replaces expensive antiviral medications like acyclovir with polyethylene glycol, a inexpensive substance that can be applied topically. PEG is applied frequently (multiple times daily) over short periods to prevent and treat herpes outbreaks, providing a cost-effective alternative that eliminates the need for expensive prescription medications while maintaining therapeutic efficacy
Solution Approach 2:
The patent changes the approach from systemic antiviral medication to topical application of polyethylene glycol. By altering the route of administration and the chemical substance used, the treatment achieves antiviral effects through a different mechanism that does not induce viral resistance and significantly reduces cost
2Reliability
If acyclovir is used to treat herpes labialis, then antiviral efficacy is achieved, but viral resistance increases
Solution Approach 1:
The patent uses polyethylene glycol as a disposable topical treatment applied frequently over short periods to prevent and treat herpes outbreaks. This approach avoids the development of viral resistance that occurs with prolonged use of antiviral medications like acyclovir, while maintaining effective control of herpes labialis through mechanical and osmotic effects on the virus
3Reliability
If antiviral medication is used to treat herpes labialis, then relapse is controlled, but patient compliance decreases
Solution Approach 1:
The patent employs polyethylene glycol as an inexpensive topical agent applied multiple times daily for short durations to prevent and treat herpes outbreaks. The low cost and over-the-counter availability of PEG significantly improve patient compliance compared to expensive prescription antivirals, while maintaining effective relapse control through consistent topical application
Solution Approach 2:
The patent enables patients to self-administer polyethylene glycol topically without requiring prescription or medical supervision. Patients can easily obtain PEG from any pharmacy and apply it themselves according to simple instructions, eliminating barriers related to doctor appointments, prescriptions, and complex dosing regimens, thereby dramatically improving compliance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PEG significantly reduces the frequency and potentially delays or prevents relapse of herpes labialis, offering a cost-effective and patient-compliant alternative with minimal side effects, as demonstrated by clinical studies.
Implementation Method 1
utilizing its hygroscopic properties to create an environment less conducive to virus replication
Data Source
Figure 1
AI summary
The present invention pertains generally to the field of therapy, and more specifically to the field of therapy for herpes simplex and herpes zoster, and more particularly, to methods of reducing the rate of relapse, delaying relapse, and/or preventing relapse of herpes labialis (cold sores on the lips), herpes genitalis (genital herpes), and herpes zoster (shingles, zona), by topical administration of polyethylene glycol (PEG), or a composition comprising PEG.